MARKET WIREMoomoo • 1d ago
BeyondSpring(BYSI) Stock Options Chain | Quotes & NewsMoomoo report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.
Why BYSI Stock surged +25.18% Today — RQD Quant Desk Flash
$0.81 +25.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.85
BeyondSpring Inc. (BYSI) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $26.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BYSI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, BeyondSpring Inc. (NASDAQ: BYSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.81 (+25.18% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BYSI ranks #545 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BYSI compare to BCTX and ABVC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BYSI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BYSI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BYSI?
▼
Per BYSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001677940), BeyondSpring Inc. generated $25.0M in revenue (+2.2% YoY), -$1.0M in net income, and -$19.8M in free cash flow against $25.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.85 (+4.34%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BYSI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY BYSI SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)
FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 53.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.61-14.8% Next Q
29
Q2 (-2Q)Grade E$0.52-11.5% Next Q
32
Q3 (-1Q)Grade E$0.46+76.1% Next Q
34
CurrentGrade D-$0.81-8.1% Hist 90D α
37
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BYSI Turnaround Squeeze
While BYSI currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.65) and Max Pain ($0.85) forces dealer call-delta covering toward $2.56.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BYSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BYSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BYSI Stock surged +25.18% Today — RQD Quant Desk Flash
BeyondSpring Inc. (BYSI) surged +25.18% to $0.81, trading at 19% of its 52-week range ($0.42 – $2.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 19% of its 52-week range ($0.42 – $2.44) with RSI-14 at 53.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.81 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BYSI Headlines & Catalysts
MARKET WIREStockInvest.us • 1d ago
Beyondspring Stock Price Forecast. Should You Buy BYSI?StockInvest.us report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Two funds underpin one manager’s reported passive stake in BeyondSpring (BYSI).Stock Titan report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
BeyondSpring (BYSI) Slips 3.90% to $0.56 as Shares Press Toward Lower Support - Diagonal Spread Tradehttps://www.dars.gov.et/ report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 1d ago
After-Hours Gainers and Losers: Nov. 2, 2026 Postmarket ReviewNov. 2, 2026 postmarket review of after-hours gainers and losers, including PARA, GMEX, BLZE, SXT, HODO and ADEA, with several stocks reversing today's moves.
MARKET WIREChartMill • 1d ago
Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026Nov. 2, 2026 US market movers: small-cap and micro-cap top gainers and decliners, led by CLRO, INLF, EVGO, DRUG, JDZG and SVRN, with percentage changes and comments.
MARKET WIREBenzinga • 4d ago
12 Health Care Stocks Moving In Friday's Intraday SessionGainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
MARKET WIREBenzinga • 12d ago
12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The
RISK WATCHSeekingAlpha • 21d ago
BeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks TranscriptBeyondSpring Inc. (BYSI) Shareholder/Analyst Call October 13, 2026 9:00 AM EDTCompany ParticipantsMin Qiu - Chief Executive OfficerPresentationUnknown...
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Monday's Intraday SessionGainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved upwards by
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BYSI)
- ✓Walkthrough of BYSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BYSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.36%▼ DESCENDING CHANNEL
2026-11-03O $0.51H $0.81L $0.51C $0.81VOL 219.1K
RES: $0.96SUP: $0.39SMA50: $0.65SMA200: $1.26
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BYSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on BYSI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BYSI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BYSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BYSI)
Health Care Rank #545 of 1015
⚔️ BCTX vs BYSI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BYSI vs. BCTX, ABVC, CPHI, CELU)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, BeyondSpring Inc. (BYSI) ranks #545 by composite RQD confidence (37/100, grade D-) and #811 by equity capitalization ($26.5M). Within this direct 5-issuer industry benchmark cohort, BYSI leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BYSI at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BYSI
ACTIVE
BeyondSpring Inc. | D- | 37/100 | — | — | -35.0% | +25.18% | $26.5M | Benchmark Subject |
| BCTX BriaCell Therapeutics Corp. | D- | 40/100 | — | — | — | +1.65% | $26.5M | /bctx-vs-bysi → |
| ABVC ABVC BioPharma Inc. | E | 32/100 | — | — | -35.0% | -1.99% | $26.7M | /abvc-vs-bysi → |
| CPHI China Pharma Holdings Inc. | D- | 35/100 | — | -3.2% | -11.4% | -2.98% | $26.9M | /cphi-vs-bysi → |
| CELU Celularity Inc. (Class A) | E | 26/100 | — | 24.4% | -35.0% | +0.30% | $26.0M | /celu-vs-bysi → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001677940 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), BeyondSpring Inc. (BYSI) reported GAAP revenue of $25.0M (+2.2% vs. FY2024 revenue of $24.5M , and -40.7% cumulative change since FY2023) , GAAP net income of -$1.0M, operating cash flow of -$19.8M, and free cash flow of -$19.8M (-18.9% YoY). On the balance sheet, BYSI closed FY2025 with $25.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $25.0M | -$1.0M | -$19.8M | -$19.8M | $25.9M | — |
| FY2024 (FY) | 2024-12-31 | $24.5M | -$11.1M | -$16.4M | -$16.7M | $34.3M | — |
| FY2023 (FY) | 2023-12-31 | $42.2M | -$21.0M | -$16.5M | -$16.5M | — | — |
3. BYSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, BeyondSpring Inc. (NASDAQ: BYSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.81 (+25.18% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BYSI ranks #545 in composite RQD confidence.
How does BYSI compare to BCTX and ABVC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BYSI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BYSI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BYSI?
Per BYSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001677940), BeyondSpring Inc. generated $25.0M in revenue (+2.2% YoY), -$1.0M in net income, and -$19.8M in free cash flow against $25.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BYSI trading relative to its 50-day, 200-day, and 52-week technical levels?
BYSI last traded at $0.81 (+25.18% on volume of 1,483,066 shares), positioning the stock +24.62% above its 50-day simple moving average ($0.65) and -35.71% below its 200-day simple moving average ($1.26). Across its 52-week range of $0.42 to $2.44, BYSI sits at the 19.3% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.91).
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ SEC XBRL & RQD VERIFIED
BYSI — BeyondSpring Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
BeyondSpring Inc. (BYSI) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.81 (+25.18% 1D, market capitalization $26.5M).
- Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
BeyondSpring Inc. Is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the sourced periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BeyondSpring Inc. (BYSI) reported $25.0M in annual revenue (up from $24.5M in FY2024, +2.2% YoY) and -$1.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($42.2M revenue, -$21.0M net income) through FY2025, BYSI scaled operating cash flow to -$19.8M and free cash flow to -$19.8M, backed by $25.9M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.42 – $2.44 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BYSI carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can BYSI sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $25.0M and free cash flow of -$19.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is BYSI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
BYSI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for BeyondSpring Inc. (BYSI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Moomoo • 1d ago
BeyondSpring(BYSI) Stock Options Chain | Quotes & News Moomoo report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 1d ago
Beyondspring Stock Price Forecast. Should You Buy BYSI? StockInvest.us report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Two funds underpin one manager’s reported passive stake in BeyondSpring (BYSI). Stock Titan report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
BeyondSpring (BYSI) Slips 3.90% to $0.56 as Shares Press Toward Lower Support - Diagonal Spread Trade https://www.dars.gov.et/ report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 1d ago
After-Hours Gainers and Losers: Nov. 2, 2026 Postmarket Review Nov. 2, 2026 postmarket review of after-hours gainers and losers, including PARA, GMEX, BLZE, SXT, HODO and ADEA, with several stocks reversing today's moves.
🟡 MARKET WIRE ChartMill • 1d ago
Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026 Nov. 2, 2026 US market movers: small-cap and micro-cap top gainers and decliners, led by CLRO, INLF, EVGO, DRUG, JDZG and SVRN, with percentage changes and comments.
🟡 MARKET WIRE Benzinga • 4d ago
12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
🟡 MARKET WIRE Benzinga • 12d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BYSI Bull vs. Bear Conversation Board — What's Your Call at $0.81?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BYSI 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $0.78 (+21.9%)
📌 Pinned Debate Price of 0.52 sits near the bottom of a $0.42 - $2.44 52-week range with a 1.0 beta, leaving room for re-rating if cash generation turn
Picked up a starter position in BYSI in my $100K Virtual Cash book at $0.64. Price of 0.52 sits near the bottom of a $0.42 - $2.44 52-week range with a 1.0 beta, leaving room for re-rating if cash generation turns positive.. Trading inside a $0.42–$2.44 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
SectorRotator 🐂 BULL
@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $0.52 (-18.8%)
Spot @ $0.64 ROIC of -35%, FCF of -$19.8M against $7.8M cash, and a Piotroski F-Score of 2/9 point to a cash engine that is not yet self-funding.
Fading this rally in BYSI at $0.64. ROIC of -35%, FCF of -$19.8M against $7.8M cash, and a Piotroski F-Score of 2/9 point to a cash engine that is not yet self-funding.. With a beta of 1.0 and the stock sitting at $0.64 (52-wk range $0.42–$2.44), the easy multiple expansion is already priced in.